Search results

Meet Altasciences' Dr. Lynne Le Sauteur, PhD, Vice President of Laboratory Sciences.

Hallucinogens, dissociatives and other Schedule I drugs are increasingly being found to have a clinical application in a number of therapeutic areas. Recent approvals, background, and related case studies in this month's blog.

The formulation of an active pharmaceutical ingredient (API) to ensure maximum bioavailability is central to successful drug development. When an API is insoluble or poorly soluble, it will require processing...